JCO Global Oncology (Sep 2023)

Africa Guidelines for Hepatocellular Carcinoma Buildup Process

  • Ghassan K. Abou-Alfa,
  • Mary Afihene,
  • Marinela Capanu,
  • Yuelin Li,
  • Joanne F. Chou,
  • Akwi Asombang,
  • Olusegun Isaac Alatise,
  • Adda Bounedjar,
  • Lina Cunha,
  • Hailemichael Desalegn Mekonnen,
  • Papa Saloum Diop,
  • Reda Elwakil,
  • Mahamat Moussa Ali,
  • Ntokozo Ndlovu,
  • Jerry Ndumbalo,
  • Precious Takondwa Makondi,
  • Christian Tzeuton,
  • Tiago Biachi de Castria,
  • Adwoa Afrakoma Agyei-Nkansah,
  • Fiyinfolu Balogun,
  • Alain Bougouma,
  • Blaise Irénée Atipo Ibara,
  • Eduard Jonas,
  • Stephen Kimani,
  • Peter Kingham,
  • Reshad Kurrimbukus,
  • Nazik Hammad,
  • Mona Fouad,
  • Noha El Baghdady,
  • Eloumou Bagnaka Servais Albert Fiacre,
  • Vikash Sewram,
  • C. Wendy Spearman,
  • Ju Dong Yang,
  • Lewis R. Roberts,
  • Ashraf O. Abdelaziz

DOI
https://doi.org/10.1200/GO.23.00159
Journal volume & issue
no. 9

Abstract

Read online

PURPOSEHepatocellular carcinoma (HCC), the fourth most common cancer in Africa, has a dismal overall survival of only 3 months like in sub-Saharan Africa. This is affected by the low gross domestic product and human development index, absence of coherent guidelines, and other factors.METHODSAn open forum for HCC-experienced health care workers from Africa and the rest of the world was held in October 2021. Participants completed a survey to help assess the real-life access to screening, diagnoses, and treatment in the North and Southern Africa (NS), East and West Africa (EW), Central Africa (C), and the rest of the world.RESULTSOf 461 participants from all relevant subspecialties, 372 were from Africa. Most African participants provided hepatitis B vaccination and treatment for hepatitis B and C. More than half of the participants use serum alpha-fetoprotein and ultrasound for surveillance. Only 20% reported using image-guided diagnostic liver biopsy. The Barcelona Clinic Liver Cancer is the most used staging system (52%). Liver transplant is available for only 28% of NS and 3% EW. C reported a significantly lower availability of resection. Availability of local therapy ranged from 94% in NS to 62% in C. Sorafenib is the most commonly used systemic therapy (66%). Only 12.9% reported access to other medications including immune checkpoint inhibitors. Besides 42% access to regorafenib in NS, second-line treatments were not provided.CONCLUSIONSimilarities and differences in the care for patients with HCC in Africa are reported. This reconfirms the major gaps in access and availability especially in C and marginally less so in EW. This is a call for concerted multidisciplinary efforts to achieve and sustain a reduction in incidence and mortality from HCC in Africa.